The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

10.1212/WNL.58.2.169

10.1212/WNL.43.5.910

1991, Lancet, 337, 441, 10.1016/0140-6736(91)93389-Q

10.1016/S0140-6736(02)12023-X

10.1212/WNL.40.2.261

10.1212/01.WNL.0000095425.84407.39

BASTIANELLO, 1994, Can. J. Neurol. Sci., 21, 266, 10.1017/S0317167100041263

MAUCH, 1999, Proceedings of the 124th Annual Meeting of the American Neurological Association

ETEMADIFAR, 2005, The World Congress of Neurology

LEPAGE, 2005, Mult. Scler., 11, S171

10.1191/1352458505ms1148oa

10.1212/01.WNL.0000159743.08996.99

EDAN, 2001, Mult. Scler., 7, S14

10.1212/WNL.63.12_suppl_6.S41

2002, NOVANTRONE (mitoxantrone) package insert

10.1016/S0022-510X(02)00335-0

10.1212/WNL.63.2.25A

10.1212/WNL.59.6.909

10.1007/BF00174159

10.1007/BF00174158

10.1212/WNL.59.6.954

10.1191/1352458504ms1047cr

FELIX, 1998, Biochem. Biophys. Acta, 140, 233

10.1016/0165-5728(86)90063-9

10.1212/WNL.43.7.1401

10.1007/s004150050066

HARTUNG HP, GONSETTE R, MORRISSEY S, KRAPF H, FAZEKAS F: Mitoxantrone. In: Rudick RA, Goodkin DE (Eds.),Multiple Sclerosis Therapeutics, London Martin Dunitz, (1999):335-348.

10.1212/01.wnl.0000174439.70369.7a

FOX E, RENEW STUDY TEAM: Evaluation of safety and tolerability of mitoxantrone in the continuation of the worsening multiple sclerosis (RENEW) study.Proceeding of the Consortium of MS Centers, Orlando, USA (2005):77.

10.1191/1352458505ms1154oa

10.1191/1352458503ms896oa

ETEMADIFAR, 2005, The World Congress of Neurology

MACLEAN, 2005, Mult. Scler., 11, S171

KALLWEIT, 2005, Mult. Scler., 11, S172

VOLLMER T, CAMPAGNOLO: Symptom control and quality of life following mitoxantrone treatment.Proceedings of Consortium of MS Centers Meeting, Orlando, USA (2005):61.

VOLLMER, 2005, Mult. Scler., 11, S87

KITA, 2005, Neurology, 64, A330

10.1212/WNL.63.12_suppl_6.S1

10.2165/00023210-200418060-00010

MAO-DRAAYER, 2005, The World Congress of Neurology

10.1212/WNL.63.12_suppl_6.S28

CAON, 2005, Neurology, 64, A329